Catalog Advanced Search
-
Contains 1 Component(s) Includes a Live Web Event on 06/27/2024 at 3:00 PM (CDT)
The Best of CAR T at the 2024 Tandem Meetings webinar will air on Thursday, June 27, at 3 p.m. CDT.
The Best of CAR T at the 2024 Tandem Meetings webinar is the first in a two-part CAR T webinar series. This session will air on Thursday, June 27, at 3 p.m. CDT and will spotlight three talks from the 2024 Tandem Meetings of ASTCT and CIBMTR. This hour-long webinar will have three, fifteen-minute talks with the remaining fifteen minutes used for audience Q&A. The session is open and free to all ASTCT members and non-members.
Presentations and Speakers:
Outpatient CAR-T in Action: Models for Staffing and Overcoming Challenges
David Porter, MD; Director, Center for Cell Therapy and Transplant, University of Pennsylvania
Role of the Microbiome in Resistance to CAR-T cell Therapies
Melody Smith, MD; Assistant Professor of Medicine, Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine
CAR T-cells and Late-Effects, Including Secondary Malignancy
Aimee Talleur, MD; Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital
If you're interested in viewing/purchasing the full session recordings from the 2024 Tandem Meetings of ASTCT and CIBMTR, please click here.
Thank you to Janssen Oncology and Legend Biotech for their generous support of this webinar series.
-
Register
- Non-member - Free!
- Member - Free!
- More Information
-
Register
-
Contains 1 Component(s) Includes a Live Web Event on 06/05/2024 at 2:00 PM (CDT)
The ASTCT Pharmacy SIG June 2024 Journal Club will air on Wednesday, June 5, 2024 at 2 pm CDT/3 pm EDT.
The ASTCT Pharmacy SIG June 2024 Journal Club will air on Wednesday, June 5, 2024 at 2 pm CDT/3 pm EDT. This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q&A session. In the June Journal Club session, Drs. Krajewski and Sowell will present on two articles related to: (a)efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation and (b)gilteritinib as post-transplant maintenance for acute myeloid leukemia. This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing CAR T-cell therapy or hematopoietic stem cell transplant.
Presenters & Articles
Kristyn Krajewski, PharmD
PGY-2 Pharmacy Resident
Hospital at the University of Pennsylvania
Hunter Sowell, PharmD
PGY-2 Pharmacy Resident
Vanderbilt University Medical Center
Session Learning Objectives:
Upon completion of the activity, participants should be able to:
- Review impact of FMS-like tyrosine kinase 3 (FLT3) mutation on prognosis and treatment of acute myeloid leukemia (AML).
- Evaluate efficacy and safety of gilteritinib as post-transplant maintenance for AML with FLT3-internal tandem duplication (ITD) mutation.
- Identify patients who are most likely to benefit from post-transplant gilteritinib maintenance.
- Review cytomegalovirus (CMV) infection prophylaxis strategies following hematopoietic stem cell transplant (HSCT).
- Analyze the efficacy and safety of extended duration letermovir prophylaxis following HSCT in patients at risk of CMV infection.
- Explore the utility of extended duration letermovir for CMV prophylaxis following HSCT.
ACCREDITED PROVIDER
This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).
In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CREDIT DESIGNATION
Pharmacists
This knowledge-based activity, qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
All other healthcare professionals completing this course will be issued a statement of participation.
The full CE information for this session can be found here.
-
Register
- Non-member - Free!
- Member - Free!
- More Information
-
Contains 1 Component(s) Includes a Live Web Event on 05/28/2024 at 11:00 AM (CDT)
The Impact of Subspecialty Palliative Care Consultation in Transplantation and Cellular Therapy will air on Tuesday, May 28, 2024 at 11 am CDT/12 pm EDT.
This webinar is the second in a series of three presented by the ASTCT Palliative Care SIG.
In this session, the speakers will review the evidence base on subspecialty palliative care for improving outcomes in patients undergoing hematopoietic stem cell transplantation and adoptive cellular therapy, and also review the active components of palliative care interventions and how to best integrate them into practice.
Speakers:
Dr. Thomas W. LeBlanc, MD, MA, MHS, FAAHPM, FASCO
Associate Professor of Medicine with Tenure
Duke Cancer InstituteDeena Levine, MD FAAP FAAHPM
Interim Division Director
Medical Director - QOLA Service
Division of Quality of Life and Palliative Care
Department of Oncology
St. Jude Children’s Research Hospital
Jason A. Webb, M.D., DFAPA, FAAHPM, FACP (he/him)
Section Chief, Palliative Care, Division of Hematology & Medical Oncology
Quality Medical Director, Palliative Care, OHSU Health
Associate Professor of Medicine & Psychiatry
OHSU School of Medicine
-
Register
- Non-member - Free!
- Member - Free!
- More Information
-
Register
-
Contains 2 Component(s)
The Review of FY 2025 IPPS Proposed Rule webinar will air on Wednesday, May 15 from 12 p.m. to 1 p.m. CDT.
Join ASTCT Director of Government Relations, Alycia Maloney, JD, and the reimbursement and policy advisors to ASTCT from Nimitt Consulting, for the Medicare FY 2025 IPPS Proposed Rule webinar on May 15 at 12 p.m. CDT.
Maloney and Nimitt will cover multiple CMS proposals for FY 2025, including the following key points:
- Proposed increases to the MS-DRG base payment rates for stem cell transplant and CAR-T/Other Immunotherapy inpatient Medicare cases, including the following:
- Allogeneic HSCT (DRG 014) payment rate of $93,891, which is approximately $11,000 more than FY 2024
- Autologous HSCT (DRGs 016 & 017) payment rate of $43,068, which is a slight decrease from the FY 2024 payment rate of $43,249
- The recently approved gene therapies for sickle cell disease and transfusion-dependent beta-thalassemia are mapped to these MS-DRGs
- MS-DRG 018 payment rate of $274,413 – an increase of approximately $16,000 from FY 2024
- MS-DRG 018 reduced payment rate of approximately $93,000 for clinical trial
- Proposed Fixed Loss Outlier Threshold amount of $49,237 – an additional loss of approximately $7,000 per case from FY 2024
- Proposed changes to the New Technology Add-on Payment policies and processes
- Proposal to pay up to 75% of the determined product cost for gene therapies used to treat sickle cell disease
- Modification of the third-year anniversary date for a potential third year of NTAP eligibility from April 1 to October 1 (would be effective for FY 2026, not FY 2025)
Comments can be submitted to CMS via https://www.regulations.gov and are due by June 10, 2024.
There will be a Q&A section at the end of the webinar, so be sure to register and submit any questions in advance that you would like answered during the webinar to info@astct.org. If you are unable to join, the recording will be made available.
Please consider sharing this webinar with your network of physicians, administrators, providers, or any other colleagues that may be interested.
-
Register
- Non-member - Free!
- Member - Free!
- More Information
- Proposed increases to the MS-DRG base payment rates for stem cell transplant and CAR-T/Other Immunotherapy inpatient Medicare cases, including the following:
-
Contains 1 Component(s)
The ASTCT Pharmacy SIG March 2024 Journal Club will air on Wednesday, March 27, 2024 at 2 pm CDT/3 pm EDT
The ASTCT Pharmacy SIG March 2024 Journal Club will air on Wednesday, March 27, 2024 at 2 pm CDT/3 pm EDT. This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q&A session. In the March Journal Club session, Drs. Anderson and Boucher will present on two articles related to (a) motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma and (b) recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving CAR T-cell therapy. This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing CAR T-cell therapy or hematopoietic stem cell transplant.
Presenters & Articles
Mallori Anderson, PharmD
PGY-2 Pharmacy Resident
WVU Medicine
Julie L. Boucher, PharmD, BCPS
PGY-2 Pharmacy Resident
Yale New Haven Hospital
Session Learning Objectives:
Upon completion of the activity, participants should be able to:
- Describe the effect of bendamustine on chimeric antigen receptor (CAR) efficacy.
- Analyze the efficacy outcomes for patients receiving bendamustine before apheresis versus bendamustine naive.
- Discuss the safety outcomes related to bendamustine exposure after CAR T-cell therapy, and the impact of prior bendamustine exposure on CAR T-cell expansion.
- Review HSC mobilization regimens available for autologous transplantation in multiple myeloma patients.
- Describe the mechanism of action of motixafortide and Granulocyte-Colony Stimulating Factor (G-CSF) to mobilize HSCs.
- Evaluate the efficacy and safety of motixafortide and G-CSF compared to plerixafor and G-CSF.
ACCREDITED PROVIDER
This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).
In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CREDIT DESIGNATION
Pharmacists
This knowledge-based activity, UAN # JA0007204-9999-24-020-L01-P qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
All other healthcare professionals completing this course will be issued a statement of participation.
The full CE information for this session can be found here.
-
Register
- Non-member - Free!
- Member - Free!
- More Information
-
Contains 2 Component(s)
Advanced Practice Providers (APPs) play a crucial role in the functioning of transplant and cellular therapy programs of all sizes. Physician Assistant and Nurse Practitioner academic programs provide little training specific to HSCT and cellular therapy. However, this area of health care requires specialized knowledge and skills. Transplant and cellular therapy programs in medical institutions must develop their own educational plans and resources. These can range from very minimal to extensive educational programs depending on the institution. In response, the ASTCT APP SIG (special interest group) identified a need for a standardized document to help better train, onboard, and educate APPs working in transplant and cellular therapy.
Introduction: Advanced Practice Providers (APPs) play a crucial role in the functioning of transplant and cellular therapy programs of all sizes. Physician Assistant and Nurse Practitioner academic programs provide little training specific to HSCT and cellular therapy. However, this area of health care requires specialized knowledge and skills. Transplant and cellular therapy programs in medical institutions must develop their own educational plans and resources. These can range from very minimal to extensive educational programs depending on the institution. In response, the ASTCT APP SIG (special interest group) identified a need for a standardized document to help better train, onboard, and educate APPs working in transplant and cellular therapy. A focus group of experienced APPs in the ASTCT SIG came together to review and update standards while including resources and user-friendly checklists. This document provides a comprehensive framework to support successful onboarding and education of new APPs who will be working with the cellular therapy patient population. It provides guidance for both the orientee and the mentor. Resources included in this document are current (within 5 years if available) and highlight established consensus guidelines, evidence-based practice & current research. Currently, the goal is to review this document every 3-5 years to maintain an up-to-date onboarding and education program moving forward.
Using This Document: This document aims to serve as a template and supplement to institutional onboarding programs. Each APP will have unique needs and baseline knowledge. As a result, this document can serve as a guide but may require changes to meet a specific need. As a new APP makes its way through this onboarding list, it is important that managers, team leads, and preceptors schedule intermittent meetings to check in and assess progress. Areas with a *** are competencies that FACT recommends. While we suggest weeks for the different objectives, preceptors and trainees will likely be working on multiple areas of this document at the same time and do not need to work in a linear fashion. The assessment section is meant to help track progress through the document as well as progress through orientation. Assessments may be based on activities, objectives, or resources. The larger assessment sections have room to leave notes for both orientee and preceptor.
Acknowledgements: a special thank you to those who made this document a reality.
Maritza Alencar, DNP, MBA, APRN-BC, BMTCN
Misty Evans, DNP, APRN, CPNP-AC, BMTCN
Mary Guay, PA-C
Chelsea Honstain, MS, FNP-C, BMTCN
Rita M. Jakubowski DNP, RN, ANP-BC, OCN, BMTCN
Sarah Jimenez DNP, AGACNP, AOCNP
Samantha Newman, MSN, PNP-AC, BMTCN
Zandra Rivera,DNP, ANP-BC, BMTCN
Liza Rodriguez, DNP, MSN, FNP-C, AOCNP
Nancy Shreve, RN, MS, FNP, BMTCN
Jannelle Vicens, DNP, MSN FNP-BC, BSN
Elizabeth Zerante MS, AGACNP-BC
-
Register
- Non-member - Free!
- Member - Free!
- More Information
-
Register
-
Contains 1 Component(s)
The ASTCT Pharmacy SIG November 2023 Journal Club will air on Wednesday, November 29, 2023 at 2 pm CST/3 pm EST.
The ASTCT Pharmacy SIG November 2023 Journal Club will air on Wednesday, November 29, 2023 at 2 pm CST/3 pm EST. This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q&A session. In the November Journal Club session, Drs. Patel and Gash will present on two articles related to (a) ciltacabtagene autoleucel or standard of care treatment in lenalidomide-refractory multiple myeloma and (b) post-transplant cyclophosphamide, abatacept, and a short course of tacrolimus (CAST) after peripheral blood haploidentical HSCT.
This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing CAR T-cell therapy or hematopoietic stem cell transplant.
Presenters & Articles
Shikha P. Patel, PharmD, BCPS
PGY-2 Pharmacy Resident
Mayo Clinic
Article: Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
Kyle Gash, PharmD
PGY-2 Pharmacy Resident
Moffitt Cancer Center
Session Learning Objectives:
Upon completion of the activity, participants should be able to:
- Review the role of CAR T-cell therapy in relapsed/refractory multiple myeloma
- Describe the mechanism of action of ciltacabtagene autoleucel
- Evaluate the efficacy and safety of ciltacabtagene autoleucel compared to standard regimens in the management of relapsed/refractory multiple myeloma
- Review graft-versus-host disease (GVHD) prophylaxis regimens following haploidentical hematopoietic stem cell transplantation (HCT)
- Analyze the safety and efficacy of post-transplant cyclophosphamide (PTCy), abatacept, and a short course of tacrolimus (CAST) for GVHD prevention
- Discuss the utility of the CAST regimen for GVHD prevention after haploidentical HCT
ACCREDITED PROVIDER
This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).
In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CREDIT DESIGNATION
Pharmacists
This knowledge-based activity, UAN JA0007204-9999-23-041-L01-P, qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
All other healthcare professionals completing this course will be issued a statement of participation.
The full CE information for this session can be found here.
-
Register
- Non-member - Free!
- Member - Free!
- More Information
-
Contains 10 Product(s)
These are all the recordings and slides of the ten sessions from the live event the 2023 AcCELLerate Forum: Creating a Sustainable Ecosystem of Cell and Gene Therapy, hosted by ASTCT™, the CIBMTR® and the National Marrow Donor Program®(NMDP)/Be The Match®. Purchase this package to get access to all ten sessions at a discounted rate!
These are the recordings and slides of the four sessions from the live event the 2023 AcCELLerate Forum: Creating a Sustainable Ecosystem of Cell and Gene Therapy, hosted by ASTCT™, the CIBMTR® and the National Marrow Donor Program®(NMDP)/Be The Match®. This live event took place on October 2 and 3, 2023. The two-day, hybrid workshop offered providers, payers, government agencies, and industry involved in the field of cell and gene therapy increased educational and advocacy opportunities. This workshop featured educational sessions bridging the gap among stakeholders, and identify ongoing needs and opportunities in the field for advocacy, measurement of value and impact, and sustainability.
Purchase this package to get access to all ten sessions at a discounted rate! Individuals who registered to attend this event live are eligible to receive access to these recordings free of charge. Please email info@astct.org to receive your discount.
-
Register
- Non-member - $80
- Member - $80
- More Information
-
Register
-
Contains 4 Component(s)
This is the recording and slides of the session presented live at the 2023 AcCELLerate Forum: Creating a Sustainable Ecosystem of Cell and Gene Therapy. The event aired live on Monday, October 2, 2023.
This is the recording and slides of the session presented live at the 2023 AcCELLerate Forum: Creating a Sustainable Ecosystem of Cell and Gene Therapy. The event aired live on Monday, October 2, 2023.
Topics include:
- CAR-T Barriers to Care
- Point of Care Manufacture of CAR T cells
- Point of Care Manufacturing: Enabling affordable and accessible advanced medicines
Session Chair:
- Boro Dropulić, PhD, MBA; Caring Cross
Speakers:
- Armin Ghobadi, MD; Washington University School of Medicine
- Marcos de Lima, MD; The Ohio State University Comprehensive Cancer Center
- Boro Dropulić, PhD, MBA; Caring Cross
-
Register
- Non-member - $10
- Member - $10
- More Information
-
Contains 4 Component(s)
This is the recording and slides of the session presented live at the 2023 AcCELLerate Forum: Creating a Sustainable Ecosystem of Cell and Gene Therapy. The event aired live on Monday, October 2, 2023.
This is the recording and slides of the session presented live at the 2023 AcCELLerate Forum: Creating a Sustainable Ecosystem of Cell and Gene Therapy. The event aired live on Monday, October 2, 2023.
Topics include:
- Pearls of Cellular Therapy Manufacturing Logistics
- Clinical Use of Mesenchymal Stem Cells (MSCs) and MSC-Exosomes: Immune Suppression, Regenerative Medicine, and Gene Delivery
- Virus-Specific T Cells
Session Chair:
- Elizabeth Shpall, MD; MD Anderson Cancer Center
Speakers:
- Ray Hornung, MBA, MBCI, CEM, CBCP; NMDP
- Elizabeth Shpall, MD; MD Anderson Cancer Center
- Adrian Gee, PhD; Center for Cell & Gene Therapy, Baylor College of Medicine Houston
-
Register
- Non-member - $10
- Member - $10
- More Information